We are studying a new CAR-T cell therapy for patients with relapsed or refractory mantle-cell lymphoma who responded partially to ibrutinib. The trial aims to evaluate its effectiveness and safety in improving patient outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Mantle Cell Lymphoma (MCL) is a type of non-Hodgkin lymphoma that originates in the lymphatic system. It can be aggressive and may recur or become resistant to treatment, leading to symptoms such as swollen lymph nodes, fever, weight loss, and night sweats.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.